Novonesis Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Ester Baiget

Algemeen directeur

€3.9m

Totale compensatie

Percentage CEO-salaris	33.3%
Dienstverband CEO	4.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ester Baiget's beloning veranderd ten opzichte van Novonesis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	€283m
Mar 31 2024	n/a	n/a	€332m
Dec 31 2023	€4m	€1m	€406m
Sep 30 2023	n/a	n/a	€430m
Jun 30 2023	n/a	n/a	€460m
Mar 31 2023	n/a	n/a	€487m
Dec 31 2022	€3m	€1m	€494m
Sep 30 2022	n/a	n/a	€460m
Jun 30 2022	n/a	n/a	€418m
Mar 31 2022	n/a	n/a	€416m
Dec 31 2021	€3m	€1m	€423m
Sep 30 2021	n/a	n/a	€427m
Jun 30 2021	n/a	n/a	€409m
Mar 31 2021	n/a	n/a	€389m
Dec 31 2020	€3m	€927k	€380m

Compensatie versus markt: De totale vergoeding ($USD 4.11M ) Ester } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 5.70M ).

Compensatie versus inkomsten: De beloning van Ester is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Ester Baiget (53 yo)

4.8yrs

Tenure

€3,903,958

Compensatie

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ester Baiget	President & CEO	4.8yrs	€3.90m	geen gegevens
Rainer Lehmann	Executive VP & CFO	less than a year	€858.60k	geen gegevens
Anders Lund	Chief Operating Officer	less than a year	€1.03m	geen gegevens
Claus Fuglsang	Chief Scientific Officer	4.2yrs	geen gegevens	geen gegevens
Tobias Bjorklund	Head of Investor Relations	no data	geen gegevens	geen gegevens
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	geen gegevens	geen gegevens
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3.6yrs	geen gegevens	geen gegevens
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.8yrs	€1.02m	geen gegevens
Amy Byrick	Executive Vice President of Human Health Biosolutions	3.6yrs	geen gegevens	geen gegevens
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	geen gegevens	geen gegevens
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	geen gegevens	geen gegevens
Peter Rosholm	Chief Executive Officer of Albumedix	8.8yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0Q4U wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jesper Brandgaard	Vice Chair of the Board	less than a year	geen gegevens	geen gegevens
Cornelis de Jong	Independent Chairman	4.8yrs	€239.07k	0.0011% DKK 2.0m
Kim Stratton	Independent Director	7.8yrs	€173.33k	geen gegevens
Kasim Kutay	Director	7.8yrs	€107.73k	0.00023% DKK 416.9k
Heine Dalsgaard	Director	4.8yrs	€143.55k	0.00065% DKK 1.2m
Lise Kaae	Director	less than a year	geen gegevens	geen gegevens
Lena Holskov	Employee Representative Director	11.8yrs	€66.91k	geen gegevens
Anders Knudsen	Employee Representative Director	11.8yrs	€71.77k	geen gegevens
Sharon James	Independent Director	4.8yrs	€143.55k	geen gegevens
Preben Nielsen	Employee Representative Director	3.7yrs	€107.73k	0.000090% DKK 163.1k
Jens Obro	Employee Representative Director	3.7yrs	€71.77k	0.00012% DKK 217.5k
Morten Otto Sommer	Independent Director	2.7yrs	€137.51k	0.00022% DKK 398.7k

4.8yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0Q4U wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Novonesis Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Novonesis A/S Announces Board Changes

Novozymes A/S Announces Board Appointments

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Recent updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Now 10% overvalued after recent price rise

Now 21% overvalued after recent price rise

Now 22% overvalued after recent price rise

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Financial position

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Now 21% undervalued after recent price drop

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.8% yield

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Upcoming Dividend of kr.5.25 Per Share

New 90-day high: kr.383

Novozymes A/S Announces Executive Appointments, Effective April 2021

Full year 2020 earnings released

Revenue misses expectations

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions